Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 81Specimen Handling 80Cyclophosphamide 72pembrolizumab 61Nivolumab 53Radiotherapy 52fludarabine 43Cisplatin 42Biopsy 40Carboplatin 38Standard of Care 35Dexamethasone 31Radiation 30Bevacizumab 30Rituximab 29Surveys and Questionnaires 27Radiosurgery 26Doxorubicin 26Temozolomide 25Gemcitabine 25Cytarabine 25Blood Specimen Collection 25venetoclax 24Practice Guidelines as Topic 24Paclitaxel 24fludarabine phosphate 23Ipilimumab 21atezolizumab 20Vincristine 20Interviews as Topic 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × ceritinib × 30 days × Clear all
NCT02321501 2026-05-20

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
37 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡